Skip to main content
Fig. 2 | BMC Medicine

Fig. 2

From: Hepatic artery infusion of FOLFOX chemotherapy plus camrelizumab combined with sorafenib for advanced hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (Double-IA-001): a phase II trial

Fig. 2

Treatment response and duration. a Best percent change from baseline in target lesions per mRECIST. b Best percent change from baseline in target lesions per RECIST 1.1. c Treatment exposure and response duration per mRECIST. d Treatment exposure and response duration per RECIST 1.1

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us